[Triple combination treatment of chronic hepatitis C].
The 2011 has brought about a significant change in the treatment of chronic hepatitis C virus (HCV) infection. This change has been enabled by commercial availability of new antiviral agents for treatment of chronic HCV infection - telaprevir and boceprevir - in combination with pegylated interferon (PEG-IFN) α and ribavirin (RBV). The triple combination is significantly more effective than the PEG-IFN and RBV combination alone in antiviral treatment-naive patients as well as in patients in whom the traditional PEG-IFN and RBV combination did not provide permanent HCV infection elimination. In treatment-naive patients, the triple combination is approximately 2-fold more effective than the standard treatment with PEG-IFN and RBV and the effect of the triple combination is 3-fold higher when used in pre-treated patients instead of repeated PEG-IFN and RBV treatment.
Klinika infekcnich chorob Lekarske fakulty MU a FN Brno. phusa@fnbrno.cz
P
P
Husa
D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D009842:Oligopeptides / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011392:Proline / Q000008:administration & dosage / Q000031:analogs & derivatives; D011480:Protease Inhibitors / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage; D012254:Ribavirin / Q000008:administration & dosage
D000998:Antiviral Agents; D016898:Interferon-alpha; D009842:Oligopeptides; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline; C100416:peginterferon alfa-2a